Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy

Prostate cancer (PC) can be kept in check by androgen deprivation therapy (ADT, usually with the androgen synthesis inhibitor abiraterone acetate or the androgen receptor antagonist such as enzalutamide) until the tumor evolves to castration-resistant prostate cancer (CRPC). The transition of hormon...

Full description

Saved in:
Bibliographic Details
Main Authors: Safae Terrisse, Laurence Zitvogel, Guido Kroemer
Format: Article
Language:English
Published: Shared Science Publishers OG 2022-11-01
Series:Microbial Cell
Subjects:
Online Access:http://microbialcell.com/researcharticles/2022a-terrisse-microbial-cell/
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850228402869501952
author Safae Terrisse
Laurence Zitvogel
Guido Kroemer
author_facet Safae Terrisse
Laurence Zitvogel
Guido Kroemer
author_sort Safae Terrisse
collection DOAJ
description Prostate cancer (PC) can be kept in check by androgen deprivation therapy (ADT, usually with the androgen synthesis inhibitor abiraterone acetate or the androgen receptor antagonist such as enzalutamide) until the tumor evolves to castration-resistant prostate cancer (CRPC). The transition of hormone-sensitive PC (HSPC) to CPRC has been explained by cancer cell-intrinsic resistance mechanisms. Recent data indicate that this transition is also marked by cancer cell-extrinsic mechanisms such as the failure of ADT-induced PC immunosurveillance, which depends on the presence of immunostimulatory bacteria in the gut. Moreover, intestinal bacteria that degrade drugs used for ADT, as well as bacteria that produce androgens, can interfere with the efficacy of ADT. Thus, specific bacteria in the gut serve as a source of testosterone, which accelerates prostate cancer progression, and men with CRPC exhibit an increased abundance of such bacteria with androgenic functions. In conclusion, the response of PC to ADT is profoundly influenced by the composition of the microbiota with its immunostimulatory, immunosuppressive and directly ADT-subversive elements.
format Article
id doaj-art-38e0ccddcaab4bac9293e84c53674d70
institution OA Journals
issn 2311-2638
language English
publishDate 2022-11-01
publisher Shared Science Publishers OG
record_format Article
series Microbial Cell
spelling doaj-art-38e0ccddcaab4bac9293e84c53674d702025-08-20T02:04:33ZengShared Science Publishers OGMicrobial Cell2311-26382022-11-0191219019410.15698/mic2022.12.787Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapySafae Terrisse0Laurence Zitvogel1Guido Kroemer2Medical Oncology, Hôpital Saint-Louis, Paris, France.INSERM U1015, Equipe Labellisée – Ligue Nationale contre le Cancer, Villejuif, France.Equipe labellisée par la Ligue contre le Cancer, Université de Paris Cité, Sorbonne Université, Institut Universitaire de France, Inserm U1138, Centre de Recherche des Cordeliers, Paris, France.Prostate cancer (PC) can be kept in check by androgen deprivation therapy (ADT, usually with the androgen synthesis inhibitor abiraterone acetate or the androgen receptor antagonist such as enzalutamide) until the tumor evolves to castration-resistant prostate cancer (CRPC). The transition of hormone-sensitive PC (HSPC) to CPRC has been explained by cancer cell-intrinsic resistance mechanisms. Recent data indicate that this transition is also marked by cancer cell-extrinsic mechanisms such as the failure of ADT-induced PC immunosurveillance, which depends on the presence of immunostimulatory bacteria in the gut. Moreover, intestinal bacteria that degrade drugs used for ADT, as well as bacteria that produce androgens, can interfere with the efficacy of ADT. Thus, specific bacteria in the gut serve as a source of testosterone, which accelerates prostate cancer progression, and men with CRPC exhibit an increased abundance of such bacteria with androgenic functions. In conclusion, the response of PC to ADT is profoundly influenced by the composition of the microbiota with its immunostimulatory, immunosuppressive and directly ADT-subversive elements.http://microbialcell.com/researcharticles/2022a-terrisse-microbial-cell/akkermansia muciniphilacastration-resistant prostate cancerhormonotherapymicrobiomeruminococcus gnavus
spellingShingle Safae Terrisse
Laurence Zitvogel
Guido Kroemer
Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy
Microbial Cell
akkermansia muciniphila
castration-resistant prostate cancer
hormonotherapy
microbiome
ruminococcus gnavus
title Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy
title_full Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy
title_fullStr Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy
title_full_unstemmed Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy
title_short Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy
title_sort effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy
topic akkermansia muciniphila
castration-resistant prostate cancer
hormonotherapy
microbiome
ruminococcus gnavus
url http://microbialcell.com/researcharticles/2022a-terrisse-microbial-cell/
work_keys_str_mv AT safaeterrisse effectsoftheintestinalmicrobiotaonprostatecancertreatmentbyandrogendeprivationtherapy
AT laurencezitvogel effectsoftheintestinalmicrobiotaonprostatecancertreatmentbyandrogendeprivationtherapy
AT guidokroemer effectsoftheintestinalmicrobiotaonprostatecancertreatmentbyandrogendeprivationtherapy